Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.

Fleischer V, Friedrich M, Rezk A, Bühler U, Witsch E, Uphaus T, Bittner S, Groppa S, Tackenberg B, Bar-Or A, Zipp F, Luessi F.

Mult Scler. 2018 Apr;24(5):632-641. doi: 10.1177/1352458517703799. Epub 2017 Apr 24.

PMID:
28436295
2.

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.

Longbrake EE, Ramsbottom MJ, Cantoni C, Ghezzi L, Cross AH, Piccio L.

Mult Scler. 2016 Jul;22(8):1061-1070. doi: 10.1177/1352458515608961. Epub 2015 Oct 12.

3.

Effects of dimethyl fumarate on lymphocyte subsets.

Berkovich R, Weiner LP.

Mult Scler Relat Disord. 2015 Jul;4(4):339-41. doi: 10.1016/j.msard.2015.06.002. Epub 2015 Jun 10.

PMID:
26195053
4.

Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.

Baharnoori M, Gonzalez CT, Chua A, Diaz-Cruz C, Healy BC, Stankiewicz J, Weiner HL, Chitnis T.

Mult Scler Relat Disord. 2018 Feb;20:51-57. doi: 10.1016/j.msard.2017.12.003. Epub 2017 Dec 14.

PMID:
29304497
5.

Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies.

Khatri BO, Tarima SS, Essig B, Sesing J, Olapo T.

Mult Scler Relat Disord. 2017 Nov;18:60-64. doi: 10.1016/j.msard.2017.09.014. Epub 2017 Sep 21.

PMID:
29141823
6.

Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.

Longbrake EE, Cantoni C, Chahin S, Cignarella F, Cross AH, Piccio L.

Mult Scler. 2018 May;24(6):728-738. doi: 10.1177/1352458517707069. Epub 2017 May 8.

7.

Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.

Cunill V, Massot M, Clemente A, Calles C, Andreu V, Núñez V, López-Gómez A, Díaz RM, Jiménez MLR, Pons J, Vives-Bauzà C, Ferrer JM.

Front Immunol. 2018 May 29;9:1097. doi: 10.3389/fimmu.2018.01097. eCollection 2018.

8.

Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile.

Medina S, Villarrubia N, Sainz de la Maza S, Lifante J, Costa-Frossard L, Roldán E, Picón C, Álvarez-Cermeño JC, Villar LM.

Mult Scler. 2018 Sep;24(10):1317-1327. doi: 10.1177/1352458517717088. Epub 2017 Jun 27.

PMID:
28653862
9.

Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients.

Montes Diaz G, Fraussen J, Van Wijmeersch B, Hupperts R, Somers V.

Sci Rep. 2018 May 29;8(1):8194. doi: 10.1038/s41598-018-26519-w.

10.

Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.

Wu Q, Wang Q, Mao G, Dowling CA, Lundy SK, Mao-Draayer Y.

J Immunol. 2017 Apr 15;198(8):3069-3080. doi: 10.4049/jimmunol.1601532. Epub 2017 Mar 3.

11.

Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.

Miclea A, Leussink VI, Hartung HP, Gold R, Hoepner R.

J Neurol. 2016 Aug;263(8):1626-32. doi: 10.1007/s00415-016-8175-3. Epub 2016 Jun 3.

PMID:
27260297
12.

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.

Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(3):e76. doi: 10.1212/NXI.0000000000000076. eCollection 2015 Jun.

13.

[Dimethyl Fumarate in Multiple Sclerosis].

Tanaka M, Shimizu Y.

Brain Nerve. 2017 Sep;69(9):1041-1046. doi: 10.11477/mf.1416200864. Review. Japanese.

PMID:
28900067
14.

Dimethyl fumarate treatment alters NK cell function in multiple sclerosis.

Smith MD, Calabresi PA, Bhargava P.

Eur J Immunol. 2018 Feb;48(2):380-383. doi: 10.1002/eji.201747277. Epub 2017 Dec 15.

15.

Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis.

Diebold M, Sievers C, Bantug G, Sanderson N, Kappos L, Kuhle J, Lindberg RLP, Derfuss T.

J Autoimmun. 2018 Jan;86:39-50. doi: 10.1016/j.jaut.2017.09.009. Epub 2017 Sep 27.

PMID:
28958667
16.

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A.

J Immunol. 2017 Jan 15;198(2):691-698. doi: 10.4049/jimmunol.1601649. Epub 2016 Dec 14. Erratum in: J Immunol. 2019 Apr 1;202(7):2172.

17.

Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.

Nicholas JA, Boster AL, Imitola J, O'Connell C, Racke MK.

Drug Des Devel Ther. 2014 Jul 7;8:897-908. doi: 10.2147/DDDT.S50962. eCollection 2014. Review.

18.

Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.

Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Centonze D, Cortese A, De Fino C, De Giglio L, Elia G, Fantozzi R, Ferraro E, Francia A, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia GA, Millefiorini E, Monteleone F, Nociti V, Salvetti M, Sgarlata E, Pozzilli C.

CNS Drugs. 2018 Oct;32(10):963-970. doi: 10.1007/s40263-018-0543-3.

PMID:
30022464
19.

Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida.

Valiathan R, Deeb K, Diamante M, Ashman M, Sachdeva N, Asthana D.

Immunobiology. 2014 Jul;219(7):487-96. doi: 10.1016/j.imbio.2014.02.010. Epub 2014 Mar 2.

PMID:
24661720
20.

Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.

Sánchez-Ramón S, Bellón JM, Resino S, Cantó-Nogués C, Gurbindo D, Ramos JT, Muñoz-Fernández MA.

Pediatrics. 2003 Feb;111(2):E168-75.

PMID:
12563091

Supplemental Content

Support Center